Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Pfizer

BioNTech SE

The CDC committee voted unanimously to recommend the shots for use in infants through preschoolers after two days of meetings that were open to the public.

CDC advisors recommend Covid vaccines for children as young as 6 months

The FDA authorized Moderna's COVID-19 vaccine for immunizing children.

Why Moderna Stock Is Rising Today

Pending the CDC's signoff, both Moderna and Pfizer shots could be available for the youngest children within days.

FDA Approves COVID Vaccines for Kids as Young as 6 Months Old

The vaccines will be available for young children once the CDC recommends them, which will likely happen this weekend.

FDA authorizes Pfizer and Moderna COVID-19 vaccines for children as young as 6 months old

The Food and Drug Administration announced Friday that it authorized the COVID-19 vaccines developed by BioNTech SE BNTX, -6.41% /Pfizer Inc. PFE, -2.12% and Moderna Inc. MRNA, -5.80% for children as young as six months old. The regulator said Moderna's two-dose vaccine is now authorized for children between the ages of 6 months old and 17 years old.

FDA authorizes both mRNA vaccines for young children

The White House expects vaccinations to begin as soon as Tuesday.

FDA authorizes Pfizer and Moderna's Covid vaccines for children as young as 6 months

The U.S. Food and Drug Administration has authorized user of the COVID-19 vaccines from Pfizer and BioNTech, and from Moderna, for kids between 6 months and 5 years of age. The FDA's decision follows a length review process, and the dosage for children under 5 is greatly reduced relative to those for older children and […]

FDA clears COVID-19 vaccines for children under 5

The approval comes just two days after an advisory panel recommended both Moderna and Pfizer vaccines for young children.

FDA Authorizes Covid Vaccines For Children As Young As 6 Months

mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart mRNA-1273 has been administered to millions of children and adolescents over the age of 6 worldwide, with safety and tolerability profiles consistent with other age groups CAMBRIDGE, MA / ACCESSWIRE / June 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine (mRNA-1273) in young children ages 6 months through 5 years of age at a dose level of 25 µg. The company has also received emergency use authorization for a 50 μg two-dose regimen of mRNA-1273 for children ages 6 through 11 years old and a 100 μg two-dose regimen for adolescents aged 12 through 17 years old.

Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older

Moderna Inc. (NASDAQ:MRNA) is trading at $128. The price is just below the support level of $140.

Moderna is a buy at $128 as it moves to re-establish support and resistance levels

Blame it on the overall stock market sell-off.

Why Pfizer, BioNTech, and Moderna Stocks Are Sinking Today

The FDA VRBPAC committee unanimously recommends the approval of both Pfizer and BioNTech and Moderna's vaccines for young children, saying the benefits of the vaccines outweigh the risks.

FDA Panel Recommends Pfizer & Moderna COVID Jabs for Young Kids

It could open a up a whole new market for Moderna's COVID-19 vaccine.

Does This FDA Panel Vote Make Moderna a Buy?

A panel of advisers to the Food and Drug Administration on Wednesdaygave its endorsement to both the Moderna MRNA, +5.73% and Pfizer PFE, +1.23% vaccines for children below the age of five, the last group to be added to the vaccine program. Advisers to the Centers for Disease Control and Prevention will now meet Friday and Saturday to finalize their recommendations, possibly clearing the path for vaccination to start next week.

Coronavirus tally: FDA panel oks Moderna and Pfizer vaccines for under-5s and Fauci tests positive for COVID

If the recommendation is backed by the FDA commissioner and the CDC, toddlers could receive their first dose as early as next week.

FDA Panel Recommends Moderna's and Pfizer's COVID Vaccine for Children as Young as 6 Months

It is generally accepted that health care stocks are a good defensive play in a declining market. It does not matter how many Teslas you have in the garage, they are not going to help if you become sick.

Of Highest-Earning Pharmas, Moderna Shares Have Suffered the Most

The FDA typically follows the recommendations of the advisory panel.

Moderna And Pfizer Covid Vaccines For Young Children Endorsed By FDA Panel

Covid Vaccine For Kids 6 Months To 5 Years Endorsed By FDA Panel

The Food and Drug Administration is expected to authorize at least one COVID-19 vaccine for the nation's youngest children in a move that may provide a choice in shots to parents who have been eager to immunize children with few protective options until this point.

FDA committee recommends Moderna's COVID-19 vaccine for young children

The FDA will likely accept the recommendation and authorize the shots this week.

Covid vaccine for kids under 5 move closer to FDA authorization after committee backs shots

Pfizer and Moderna have COVID-19 vaccines for babies as young as 6 months old up for review. Shots could begin next week.

FDA panel recommends authorizing Moderna's COVID-19 vaccine for babies and little kids

Moderna, Inc. (NASDAQ:MRNA ) 43rd Annual Goldman Sachs Global Healthcare Conference Call June 14, 2022 12:20 PM ET Company Participants Lavina Talukdar - Head, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good morning, everyone. Really pleased to have Moderna here with us.

Moderna, Inc. (MRNA) Management Presents at 43rd Annual Goldman Sachs Global Healthcare Conference (Transcript)

An FDA advisory committee voted in favor of the use of Moderna's (MRNA) COVID-19 vaccine in individuals aged 6 years to 17 years. A meeting to discuss the use of the vaccine in the younger population is scheduled for today.

Moderna's (MRNA) COVID-19 Vaccine Nears EUA in Pediatrics

Novavax

Novavax and Moderna both are betting on the booster market.

Could This News From Moderna Mean Trouble for Novavax?

If the FDA gives the official OK, there will be a second COVID-19 vaccine option for kids and teens.

News for Moderna Stock (MRNA)